Atreca Inc (BCEL)

Overview

Atreca, Inc. is a clinical-stage biopharmaceutical company that is at the forefront of developing antibody-based immunotherapeutics aimed at tackling a variety of solid tumor cancers. Through its innovative discovery platform, Atreca has been successful in identifying unique antibodies that have led to the creation of novel therapeutic candidates. The company's focus is not only on treating different forms of cancer but also on combating infectious diseases such as malaria. Founded in 2010 and headquartered in San Carlos, California, Atreca has positioned itself as a leader in the discovery and development of therapeutic antibodies, thanks to its strategic collaboration and licensing agreements that have expanded its research and development capabilities as well as its product pipeline.

Products and Services

• ATRC-101

  Atreca's lead product candidate, ATRC-101, is a monoclonal antibody featuring a novel mechanism of action derived from an antibody identified through the company's discovery platform. This candidate demonstrates the capability to react in vitro with a broad range of cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancer samples. The wide reactivity indicates its potential application across a variety of cancer treatments.

• ATRC-501/MAM01

  A specialized treatment targeting the circumsporozoite protein of Plasmodium falciparum, ATRC-501/MAM01 is Atreca's notable contribution to the fight against malaria. This candidate stands out for its innovative approach to preventing malaria, demonstrating Atreca's commitment to addressing infectious diseases alongside cancer.

• APN-497444

  In the pre-clinical stage, APN-497444 is an antibody-drug conjugate (ADC) that targets a novel tumor glycan. This product highlights Atreca's ongoing efforts to expand its portfolio with treatments that can specifically target and destroy cancer cells, promising a new direction in cancer therapy.

• APN-346958

  Another promising pre-clinical stage product, APN-346958 represents a CD3 bispecific T-cell engager. This innovative treatment targets an RNA-binding protein and is indicative of Atreca's exploration into therapies that could harness the body's immune system to fight cancer more effectively.